This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.

fool.com - 2026-06-27 15:28:05

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.

fool.com - 2026-06-24 17:24:01

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-06-12 13:01:14

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-06-10 10:56:04

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.

fool.com - 2026-05-31 10:21:54

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.

globenewswire.com - 2026-05-28 08:00:00

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026

globenewswire.com - 2026-05-13 16:03:00

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.

fool.com - 2026-05-13 15:49:47

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

prnewswire.com - 2026-05-06 08:00:00

Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind, placebo-controlled phase II study evaluating ORKA-001, the company's extended half-life IL-23/p19 monoclonal antibody for moderate-to-severe plaque psoriasis. Management highlighted what it described as a potentially "category-winning" efficacy profile alongside a safety profile consistent with the IL-23 inhibitor class, and pointed to pharmacokinetic data supporting

defenseworld.net - 2026-04-29 15:13:31

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.

globenewswire.com - 2026-04-28 19:42:00

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

seekingalpha.com - 2026-04-27 16:41:40

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

globenewswire.com - 2026-04-27 16:17:00

Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001's half-life extension technology targets once-yearly dosing, aiming for best-in-class efficacy and competitive differentiation in a crowded biologics market. Key near-term catalysts include longer-term phase 2a follow-up data in H2 2026 and phase 2b EVERLAST-B dose-finding results in 2027 for ORKA-001.

seekingalpha.com - 2026-04-27 15:51:39

Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis.

benzinga.com - 2026-04-27 10:47:53

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif.

globenewswire.com - 2026-04-27 07:00:00

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

globenewswire.com - 2026-04-26 12:00:00

MENLO PARK, Calif. , April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026.

globenewswire.com - 2026-04-26 12:00:00

7,000 shares directly sold for a value of $463,000 on April 15, 2026, at a weighted average sale price of around $66.12 per share. This transaction represented 17% of Joana Goncalves's direct Common Stock holdings, reducing her direct position from 40,377 to 33,377 shares.

fool.com - 2026-04-21 12:22:39

Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $40.00 to $70.00. HC Wainwright currently has a buy rating on the stock. Oruka Therapeutics traded as high as $65.64 and last traded at $66.1010,

defenseworld.net - 2026-04-15 02:19:39